Agenus Inc.

AGEN | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.64

+$0.31 (+3.72%)

Sep 22, 2026, 1:15 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.72%

(1D)

Rating

Updated: Aug 24, 2026

52.5

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $359.79M

1D Range

8.19 8.74

52W Range

2.71 8.85

Valuation (TTM)

PE 3.14

PB -1.74

EV/EBITDA 2.37

Valuation (NTM)

Forward PE 3.95

Forward PEG -0.01

Price Target $25

Cash Flow

FCF Yield -28.4%

SBC Adj. FCF Yield -31.4%

SBC Impact -10.5%

Margins

Gross Margin 75.6%

Operating Margin 27.3%

FCF Margin -74.2%

Growth (CAGR)

Revenue 3Y | 5Y 10.1% | 14.1%

Dil EPS 3Y | 5Y 132.6% | 23.5%

FCF 3Y | 5Y 31.9% | -0.5%

Returns

ROA 53.3%

ROE -38.1%

ROIC -129.5%

Financial Health

Net Debt

$11.33M

Current Ratio 0.34

Interest Coverage 0.61

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes ...

Sector Healthcare

Industry Biotechnology

Employees 81

IPO Date Feb 7, 2000

Website www.agenusbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$25

Upside

+189.35%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞